Ginkgo Bioworks Holdings Inc vs Monster Beverage Corp — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Monster Beverage Corp trades at $98.03 (market cap $95.85B). The key difference: Monster Beverage Corp is far larger — about 162.3× Ginkgo Bioworks Holdings Inc's market cap, and Monster Beverage Corp is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | MNST | |
|---|---|---|
Market Cap | $590.53M | $95.85B |
Sector | Health | Consumer Staples |
52-Week High | $16.14 | $98.01 |
52-Week Low | $5.48 | $58.65 |
Enterprise Value | $627.78M | $94.15B |
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Monster Beverage (MNST) trades at $97.07, down 0.33% on the day, with strong technical bullish signals from moving averages and a neutral RSI. The company demonstrates robust fundamentals with 2025 revenue of $8.29B, net income of $1.91B, and consistent earnings beats. Recent corporate actions include a 2-for-1 stock split effective August 11, 2026, reflecting management confidence in continued growth prospects.
MNST presents a compelling growth story with accelerating international expansion and product innovation driving market share gains. However, premium valuation multiples (P/E 46.89, P/S 10.89) create vulnerability to earnings disappointments. Analyst consensus remains positive with 53% buy ratings, though the $94.60 price target suggests limited near-term upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →